Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. CytoDyn Inc (CYDY) Message Board

A one-two punch could still knock us out. Could d

Message Board Public Reply | Private Reply | Keep | Replies (4)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 153887
(Total Views: 645)
Posted On: 01/13/2021 1:54:57 PM
Posted By: Borel Fields
Re: CDiddy #72556
A one-two punch could still knock us out. Could deaths in control be under, say 30, which would definitely mean no significant benefit?

The board has talked continuously about the death rate in the "control group," but we should have been more careful to say the "available-for-control population." Consider as follows:

We've discussed population severity comparability, changes in SOC, stress of high load periods and the need to consider the results from the specific hospitals in the trial. I stand by my comment that 28% to 35% (OK, 36%) reflects the sense of this board on that number. Of course, the board could be wrong.

But what if we knew the perfectly-case-comparable death rate at our trial hospitals was at the low end at 28%? Unfortunately, that's not the relevant comparison. We might have also randomly drawn a really healthy 131 patients from the pool of potential controls at those hospitals - there is a 20% chance you would draw 30 or less (23%) deaths. That's the one-two punch we can't handle.

Of course it's equally likely such randomness would work in our favor. I don't think I've been fully recognizing the size of that risk, though. However, it in no way changes prior "significance boundary" calcs, as they refer to observed results.


(1)
(0)




CytoDyn Inc (CYDY) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us